文献速递神经肿瘤

泌乳素瘤的影像学与激素消退:治疗失败分析

Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
PubMed 文献 · World Neurosurg · 2019-06-07

本研究回顾性分析3家三级医疗中心99例泌乳素瘤患者,评估多巴胺激动剂(DA)治疗下肿瘤体积和泌乳素(PRL)水平的消退规律。模型显示肿瘤体积在12.6个月时 plateau 于初始体积的68.2%,PRL在3.3个月时 plateau 于21.4 ng/mL。结论认为DA治疗第一年内PRL和体积消退达到平台,12个月时若无体积消退且PRL未正常化,可考虑其他治疗策略。

要点

  • DA治疗下泌乳素瘤PRL水平约3.3个月达平台,肿瘤体积约12.6个月达平台。
  • 12个月时缺乏体积消退且PRL未正常化,可视为DA治疗失败并考虑换策略。
  • 男性性别与更快的PRL应答相关(OR 0.168,P=0.036)。

核心结论

  • 泌乳素瘤在DA治疗第一年内PRL水平和体积消退速率达到平台。
  • 12个月时无体积消退且PRL未正常化者,可考虑其他管理策略。

研究设计与样本

  • 回顾性队列分析,检索3家三级医疗机构的电子病历,纳入99例泌乳素瘤患者。
  • 主要结局为不同时间点的肿瘤体积和PRL水平,次要结局为治疗失败指标。
  • 采用线性和指数模型、多因素及回归分析评估应答幅度和治疗失败的预测因素。

主要发现

  • 患者平均年龄42.7岁±14.5,男性占53%,诊断时平均肿瘤宽度12.3 mm、体积1.3 cm³。
  • 诊断时平均PRL水平为593.2 ng/mL(范围79-7913)。
  • 模型显示肿瘤体积在12.6个月时 plateau 于初始体积的68.2%(95%CI 61.7-73.5)。
  • PRL在3.3个月时 plateau 于21.4 ng/mL(95%CI 0-92.5)。
  • 多因素分析显示男性性别是PRL更快应答的预测因素(OR 0.168;P=0.036)。

临床怎么用

  • DA治疗泌乳素瘤时,可在3-6个月评估PRL应答,12个月评估体积消退。
  • 若12个月时PRL未正常化且肿瘤体积无消退,应讨论手术或放疗等替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: First-line treatment for prolactin-producing pituitary adenomas is dopamine agonist (DA) therapy. This is the first study to analyze the rate of radiographic and hormonal regression of prolactinomas in response to DA therapy to better understand what time frame we consider DA treatment failure. METHODS: We searched the electronic medical records of 3 tertiary care medical institutions for patients with prolactinomas. The primary outcome was tumor volume and prolactin (PRL) levels at various time points. The secondary outcome was indicators of treatment failure. Modeling by both linear and exponential models was tested to determine potential predictors of response magnitude and treatment failure by multivariate and regression analyses respectively. RESULTS: There were 99 patients (53% male) included in this analysis. The mean patient age was 42.7 years ± 14.5, and mean width/volume of tumor at diagnosis was 12.3 mm and 1.3 cm3, respectively. The mean PRL level at diagnosis was 593.2 ng/mL (79-7913). Modeling indicated a plateau at 68.2% initial volume (95% confidence interval 61.7-73.5) by 12.6 months and a PRL plateau of 21.4 ng/mL (95% confidence interval 0-92.5) by 3.3 months. Multivariate analyses revealed male sex (odds ratio 0.168; P = 0.036) to be a predictor of faster PRL response to DA therapy. CONCLUSIONS: Prolactinomas plateau in PRL levels and the rate of size regression within the first year of DA treatment. Prolactinomas with lack of size regression and failure to reach normalization of PRL levels by 12 months may be considered for other management strategies.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Akinduro OO, Lu VM, Izzo A, et al. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. World Neurosurg. 2019. PMID: 31181361. doi:10.1016/j.wneu.2019.05.249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。